Literature DB >> 26355392

Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.

Nicole Naumann1, Juliana Schwaab1, Georgia Metzgeroth1, Mohamad Jawhar1, Claudia Haferlach2, Gudrun Göhring3, Brigitte Schlegelberger3, Christian T Dietz1, Susanne Schnittger2, Sina Lotfi4, Michael Gärtner5, Tu-Anh Dang6, Wolf-Karsten Hofmann1, Nicholas C P Cross7,8, Andreas Reiter1, Alice Fabarius1.   

Abstract

In eosinophilia-associated myeloproliferative neoplasms (MPN-eo), constitutive activation of protein tyrosine kinases (TK) as consequence of translocations, inversions, or insertions and creation of TK fusion genes is recurrently observed. The most commonly involved TK and their potential TK inhibitors include PDGFRA at 4q12 or PDGFRB at 5q33 (imatinib), FGFR1 at 8p11 (ponatinib), and JAK2 at 9p24 (ruxolitinib). We here report the identification of three new PDGFRB fusion genes in three male MPN-eo patients: MPRIP-PDGFRB in a case with t(5;17)(q33;p11), CPSF6-PDGFRB in a case with t(5;12)(q33;q15), and GOLGB1-PDGFRB in a case with t(3;5)(q13;q33). The fusion proteins identified by 5'-rapid amplification of cDNA ends polymerase chain reaction (PCR) or DNA-based long distance inverse PCR are predicted to contain the TK domain of PDGFRB. The partner genes contain domains like coiled-coil structures, which are likely to cause dimerization and activation of the TK. In all patients, imatinib induced rapid and durable complete remissions.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26355392     DOI: 10.1002/gcc.22287

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Cardiac intimal sarcoma with PDGFRβ mutation and co-amplification of PDGFRα and MDM2: an autopsy case analyzed by whole-exome sequencing.

Authors:  Yukinobu Ito; Daichi Maeda; Makoto Yoshida; Akihiko Yoshida; Yukitsugu Kudo-Asabe; Hiroshi Nanjyo; Chikako Izumi; Fumio Yamamoto; Masahiro Inoue; Hiroyuki Shibata; Hiroto Katoh; Shumpei Ishikawa; Hiromi Nakamura; Yasushi Totoki; Tatsuhiro Shibata; Shinichi Yachida; Akiteru Goto
Journal:  Virchows Arch       Date:  2017-05-04       Impact factor: 4.064

2.  A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion.

Authors:  Christopher A Miller; Christopher Tricarico; Zachary L Skidmore; Geoffrey L Uy; Yi-Shan Lee; Anjum Hassan; Michelle D O'Laughlin; Heather Schmidt; Ling Tian; Eric J Duncavage; Malachi Griffith; Obi L Griffith; John S Welch; Lukas D Wartman
Journal:  Blood Adv       Date:  2018-06-12

3.  Association of Abl interactor 2, ABI2, with platelet/lymphocyte ratio in patients with renal cell carcinoma: A pilot study.

Authors:  Sercan Ergun; Sezgin Gunes; Recep Buyukalpelli; Oguz Aydin
Journal:  Int J Exp Pathol       Date:  2020-06-04       Impact factor: 1.925

4.  Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.

Authors:  Xiaoyu Xu; Qiongyu Lu; Zheng Wang; Ping Cai; Zhao Zeng; Ling Zhang; Man Wang; Liang Ma; Changgeng Ruan; Suning Chen
Journal:  Cancer Res Treat       Date:  2020-12-24       Impact factor: 4.679

5.  A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).

Authors:  Yue Zhang; Shiqiang Qu; Qianfei Wang; Jianyong Li; Zefeng Xu; Tiejun Qin; Gang Huang; Zhijian Xiao
Journal:  Leuk Lymphoma       Date:  2018-01-31

6.  A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?

Authors:  E Troadec; S Dobbelstein; P Bertrand; N Faumont; F Trimoreau; M Touati; J Chauzeix; B Petit; D Bordessoule; J Feuillard; C Bastard; N Gachard
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528

7.  Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11).

Authors:  Guangying Sheng; Zhao Zeng; Jinlan Pan; Linbing Kou; Qinrong Wang; Hong Yao; Lijun Wen; Liang Ma; Depei Wu; Huiying Qiu; Suning Chen
Journal:  Mol Cytogenet       Date:  2017-02-27       Impact factor: 2.009

8.  A novel low-grade nasopharyngeal adenocarcinoma characterized by a GOLGB1-BRAF fusion gene.

Authors:  Justin Bubola; Cristina R Antonescu; Ilan Weinreb; David Swanson; John R De Almeida; Christina M MacMillan; Brendan C Dickson
Journal:  Genes Chromosomes Cancer       Date:  2020-09-29       Impact factor: 5.006

9.  Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation.

Authors:  Cristiane M Ida; Derek R Johnson; Asha A Nair; Jaime Davila; Thomas M Kollmeyer; Kay Minn; Numrah M Fadra; Jessica R Balcom; Kar-Ming A Fung; Dong Kun Kim; Timothy J Kaufmann; Benjamin R Kipp; Kevin C Halling; Robert B Jenkins; Caterina Giannini
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-27       Impact factor: 3.685

10.  Ribonucleic acid-binding protein CPSF6 promotes glycolysis and suppresses apoptosis in hepatocellular carcinoma cells by inhibiting the BTG2 expression.

Authors:  Yang Liu; Hongbo Zou; Qichao Xie; Lan Zou; Rui Kong; Bijing Mao
Journal:  Biomed Eng Online       Date:  2021-07-03       Impact factor: 2.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.